ReviewFrontiers in neurology2025
Comparative impact of different weight loss strategies on obstructive sleep apnea: an integrated review of surgical, pharmacological, and lifestyle interventions.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is recognized as one of the most significant risk factors for obstructive sleep apnea (OSA), and weight reduction remains an effective strategy for improving OSA symptoms. With the ongoing evolution of bariatric surgery, pharmacological therapies, and conventional weight management approaches such as dietary modification and exercise, there is growing interest in understanding the differential efficacy and mechanisms of these interventions for OSA management. This review systematically examines the impacts of surgical procedures (including bariatric surgeries like gastric sleeve), pharmacological treatments (such as GLP-1 receptor agonists, orlistat, and phentermine/topiramate), and lifestyle-based weight management on OSA outcomes. It analyzes the comparative effectiveness, underlying mechanisms, indications, and limitations of each approach, integrating insights from the latest clinical studies. Additionally, this review discusses the challenges and unresolved issues in the field, such as patient selection, long-term adherence, and the interplay between weight loss and OSA pathophysiology. The purpose of this article is to provide a comprehensive synthesis of current evidence, highlight gaps in knowledge, and outline future directions for integrating weight management strategies into the holistic care of patients with OSA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.